ALCLS Cellectis SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, May 06, 2024 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

DateTotal number of shares

in the capital		Total number of voting rights
04/30/202471,955,53577,891,229

For further information on Cellectis, please contact:     

Media contact:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,   

Investor Relations contacts:       

Arthur Stril, Chief Financial Officer (interim), +1 (347) 809 5980,

Ashley R. Robinson, LifeSci Advisors, +1 617 430 7577  

 

Attachment



EN
06/05/2024

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 16 mai 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actionscomposant le capital socialNombre total de droits de vote03/05/202499 955 53587 891 239 Pour de plus amples informations sur Cellectis, veuillez contacter :         Contact média :        Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chie...

May 16, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 16, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights05/03/202499,955,53587,891,239 For further information on Cellectis, please contact:      Media contact:       Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, Investor Relations contacts:...

May 16, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Monthly information on share capital and company voting rights

Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority) PARIS, May 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights04/30/202471,955,53577,891,229 For further information on Cellectis, please contact:      Media contact:        Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93,    Investor Relations cont...

May 6, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Information mensuelle relative au nombre total des droits de vote et d...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 06 mai 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 DateNombre total d’actions composant le capital socialNombre total de droits de vote30/04/202471 955 53577 891 229 Pour de plus amples informations sur Cellectis, veuillez contacter :         Contact média :         Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, Patricia Sosa Navarro, ...

May 6, 2024 1 EN
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Announces Completion of the Additional Equity Investment by ...

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions, AstraZeneca (LSE/STO/Nasdaq: AZN) co...

May 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch